Literature DB >> 30303922

Complication Rates and Outcomes After Hysterectomy in Transgender Men.

C Emi Bretschneider1, David Sheyn, Robert Pollard, Cecile A Ferrando.   

Abstract

OBJECTIVE: To describe the rate and 30-day outcomes after gender affirmation surgery in transgender men.
METHODS: We conducted a cross-sectional population-based study. Patients with male gender who underwent hysterectomy for benign indications between 2013 and 2016 in the American College of Surgeons' National Surgical Quality Improvement database were identified. Propensity score matching was performed to ameliorate selection bias. Student t test and Mann-Whitney tests were used to compare continuous variables between two groups where appropriate. The χ and Fisher exact tests were used where appropriate to compare categorical variables across groups. Logistic regression models were used to evaluate factors associated with any postoperative adverse event.
RESULTS: Of 159,736 hysterectomies performed during the study period, 521 (0.3%) were performed in transgender men. The mean age was 23.9±13.8 years, and the median body mass index was 29.0 (range 24.8-34.2). The majority of patients were white (64.5%). The most common specified diagnosis associated with hysterectomy was gender identity disorder (20.9%). Laparoscopy was the most common route (57.2%) followed by laparoscopic-assisted vaginal hysterectomy (20.0%) and abdominal hysterectomy (15.2%). After propensity matching was performed, the composite rate of postoperative complications was similar between the transgender male and control groups (3.4% vs 3.3%, P=.92). On multivariate logistic regression controlling for age, presence of a major medical comorbidity, and primary mode of surgery, transgender male status and presence of a major medical comorbidity were not significantly associated with complications (adjusted odds ratio [OR] 1.11, 95% CI 0.56-2.10 and adjusted OR 1.16, 95% CI 0.58-2.27, respectively). Age remained weakly associated with postoperative complications (adjusted OR 1.04, 95% CI 1.01-1.06), whereas minimally invasive approaches to hysterectomy were significantly associated with lower incidences of complications (vaginal, adjusted OR 0.04, 95% CI 0.002-0.17; laparoscopic adjusted OR 0.09, 95% CI 0.04-0.18; and laparoscopic-assisted vaginal hysterectomy, adjusted OR 0.07, 95% CI 0.02-0.20).
CONCLUSION: Less than 1% of hysterectomies performed annually are for transgender male patients. Postoperative complications after hysterectomy in this patient population are similar to the complication rates found in cisgender women.

Entities:  

Mesh:

Year:  2018        PMID: 30303922     DOI: 10.1097/AOG.0000000000002936

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Body Mass Index Requirements for Gender-Affirming Surgeries Are Not Empirically Based.

Authors:  Lisa M Brownstone; Jaclyn DeRieux; Devin A Kelly; Lanie J Sumlin; Jennifer L Gaudiani
Journal:  Transgend Health       Date:  2021-06-02

2.  Combined Mastectomy and Laparoscopic Hysterectomy with Salpingo-Oophorectomy in Transgender Men: a Cohort Study.

Authors:  Daniela Gold; Marie-Christine Bertholin Y Galvez; Christian Laback; Riccarda Hartleb; Gordana Tomasch; Stephanie Schöpfer; Vesna Bjelic-Radisic; Rüdiger Hochstätter; Gunda Pristauz-Telsnigg; Rene Laky; Philipp Reif; Arnim Bader; Karl Tamussino
Journal:  Reprod Sci       Date:  2021-10-05       Impact factor: 3.060

Review 3.  Managing Dermatologic Effects of Gender-Affirming Therapy in Transgender Adolescents.

Authors:  Christina Huang; Sarah Gold; Rakan Radi; Seth Amos; Howa Yeung
Journal:  Adolesc Health Med Ther       Date:  2022-10-07

4.  Feasibility, Safety, and Satisfaction of Combined Hysterectomy with Bilateral Salpingo-Oophorectomy and Chest Surgery in Transgender and Gender Non-Conforming Individuals.

Authors:  Ilaria Mancini; Davide Tarditi; Giulia Gava; Stefania Alvisi; Luca Contu; Paolo Giovanni Morselli; Giulia Giacomelli; Alessandra Lami; Renato Seracchioli; Maria Cristina Meriggiola
Journal:  Int J Environ Res Public Health       Date:  2021-07-03       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.